Episode 121: A Conversation With an ASH President

Martin Tallman Headshot for Podcast Episode with Chadi Nabhan

Episode 121: A Conversation With an ASH President

In this special episode, Chadi hosts his previous mentor from his days as a fellow at Northwestern: Martin Tallman, MD, previous president of the American Society of Hematology (ASH) and world renowned leukemia expert. Together, they discuss mentorship and what makes a good mentor, where Dr. Tallman’s interest in leukemia came from and why he decided to begin his career in Seattle, his road to becoming an ASH president and how his day-to-day responsibilities changed after his election, reasons for becoming more active on MedTwitter, and the progression of leukemia treatment in 30+ years, along with much more.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More